Longeveron (LGVN) Competitors

Longeveron logo
$1.52 -0.09 (-5.59%)
Closing price 02/7/2025 04:00 PM Eastern
Extended Trading
$1.50 -0.02 (-0.99%)
As of 02/7/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LGVN vs. ORMP, IMUX, CLLS, CTOR, ALTS, IGMS, DBVT, ADAG, AVTX, and TNYA

Should you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include Oramed Pharmaceuticals (ORMP), Immunic (IMUX), Cellectis (CLLS), Citius Oncology (CTOR), Janone (ALTS), IGM Biosciences (IGMS), DBV Technologies (DBVT), Adagene (ADAG), Avalo Therapeutics (AVTX), and Tenaya Therapeutics (TNYA). These companies are all part of the "pharmaceutical products" industry.

Longeveron vs.

Oramed Pharmaceuticals (NASDAQ:ORMP) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

In the previous week, Oramed Pharmaceuticals had 2 more articles in the media than Longeveron. MarketBeat recorded 2 mentions for Oramed Pharmaceuticals and 0 mentions for Longeveron. Oramed Pharmaceuticals' average media sentiment score of 0.25 beat Longeveron's score of 0.00 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Oramed Pharmaceuticals Neutral
Longeveron Neutral

Longeveron has a consensus price target of $8.67, suggesting a potential upside of 470.18%. Given Longeveron's stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than Oramed Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oramed Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Longeveron
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25

Oramed Pharmaceuticals has higher revenue and earnings than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oramed Pharmaceuticals$1.34M65.28$5.53M$0.1119.73
Longeveron$710K31.77-$21.41M-$6.28-0.24

Oramed Pharmaceuticals received 303 more outperform votes than Longeveron when rated by MarketBeat users. However, 94.12% of users gave Longeveron an outperform vote while only 72.83% of users gave Oramed Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Oramed PharmaceuticalsOutperform Votes
319
72.83%
Underperform Votes
119
27.17%
LongeveronOutperform Votes
16
94.12%
Underperform Votes
1
5.88%

Oramed Pharmaceuticals has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500.

12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 13.7% of Oramed Pharmaceuticals shares are held by insiders. Comparatively, 19.1% of Longeveron shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Oramed Pharmaceuticals has a net margin of 0.00% compared to Longeveron's net margin of -967.49%. Oramed Pharmaceuticals' return on equity of -7.27% beat Longeveron's return on equity.

Company Net Margins Return on Equity Return on Assets
Oramed PharmaceuticalsN/A -7.27% -6.20%
Longeveron -967.49%-142.43%-100.84%

Summary

Oramed Pharmaceuticals beats Longeveron on 13 of the 19 factors compared between the two stocks.

Get Longeveron News Delivered to You Automatically

Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LGVN vs. The Competition

MetricLongeveronPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$22.56M$6.95B$5.70B$8.97B
Dividend YieldN/A2.91%5.30%4.00%
P/E Ratio-0.249.0086.8719.16
Price / Sales31.77218.99978.9563.35
Price / CashN/A75.4646.0638.79
Price / Book0.575.655.134.75
Net Income-$21.41M$124.14M$113.67M$222.45M
7 Day Performance3.40%0.17%0.55%1.08%
1 Month Performance-15.08%0.06%4.01%2.23%
1 Year Performance-71.09%5.53%21.91%19.93%

Longeveron Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LGVN
Longeveron
2.4434 of 5 stars
$1.52
-5.6%
$8.67
+470.2%
-71.1%$22.56M$710,000.00-0.2420
ORMP
Oramed Pharmaceuticals
1.4318 of 5 stars
$2.16
-3.6%
N/A-23.9%$87.07M$1.34M19.6410Positive News
Gap Down
IMUX
Immunic
3.5494 of 5 stars
$0.97
-1.0%
$12.67
+1,212.1%
-21.3%$86.96MN/A-0.7870
CLLS
Cellectis
2.5771 of 5 stars
$1.56
-3.1%
$7.00
+348.7%
-50.0%$86.71M$9.19M-1.20290Positive News
Gap Down
CTOR
Citius Oncology
N/A$1.21
+0.7%
$3.00
+147.9%
N/A$86.58MN/A0.00N/A
ALTS
Janone
N/A$6.05
-8.3%
N/AN/A$85.12M$39.61M0.00170Positive News
Gap Down
IGMS
IGM Biosciences
4.772 of 5 stars
$1.43
-5.3%
$5.50
+284.6%
-90.2%$85.03M$2.92M-0.39190
DBVT
DBV Technologies
3.1982 of 5 stars
$4.13
-2.5%
$22.50
+445.5%
-50.5%$84.85M$15.73M-0.9280Analyst Forecast
News Coverage
Gap Down
ADAG
Adagene
2.6553 of 5 stars
$1.90
+0.1%
$8.00
+320.8%
-53.3%$84.16M$18.11M0.00260
AVTX
Avalo Therapeutics
3.0165 of 5 stars
$8.02
-4.8%
$40.00
+398.8%
+74.8%$83.33M$1.92M0.0040Gap Down
TNYA
Tenaya Therapeutics
3.8047 of 5 stars
$1.05
-0.9%
$17.33
+1,550.8%
-83.0%$83.18MN/A-0.73110

Related Companies and Tools


This page (NASDAQ:LGVN) was last updated on 2/10/2025 by MarketBeat.com Staff
From Our Partners